JP2015522033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522033A5 JP2015522033A5 JP2015520604A JP2015520604A JP2015522033A5 JP 2015522033 A5 JP2015522033 A5 JP 2015522033A5 JP 2015520604 A JP2015520604 A JP 2015520604A JP 2015520604 A JP2015520604 A JP 2015520604A JP 2015522033 A5 JP2015522033 A5 JP 2015522033A5
- Authority
- JP
- Japan
- Prior art keywords
- neuromuscular blocking
- blocking substance
- pharmaceutically acceptable
- neuromuscular
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000903 blocking effect Effects 0.000 claims description 51
- 239000000126 substance Substances 0.000 claims description 51
- 230000002232 neuromuscular Effects 0.000 claims description 47
- -1 methylenedioxy Chemical group 0.000 claims description 32
- 241000124008 Mammalia Species 0.000 claims description 19
- 239000005557 antagonist Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 11
- 229930195710 D‐cysteine Natural products 0.000 claims description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 9
- 239000000842 neuromuscular blocking agent Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 206010029315 Neuromuscular blockade Diseases 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 5
- 229960004308 acetylcysteine Drugs 0.000 claims description 5
- 229960001570 ademetionine Drugs 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 229960001639 penicillamine Drugs 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 241000790917 Dioxys <bee> Species 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 239000004201 L-cysteine Substances 0.000 claims description 2
- 235000013878 L-cysteine Nutrition 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 150000005690 diesters Chemical class 0.000 claims description 2
- 238000002695 general anesthesia Methods 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- SJLBIPLIGYWGJV-UHFFFAOYSA-N N-nitroso-N-methyl-4-aminobutyric acid Chemical compound O=NN(C)CCCC(O)=O SJLBIPLIGYWGJV-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666244P | 2012-06-29 | 2012-06-29 | |
| US61/666,244 | 2012-06-29 | ||
| US201261703991P | 2012-09-21 | 2012-09-21 | |
| US61/703,991 | 2012-09-21 | ||
| US201361817706P | 2013-04-30 | 2013-04-30 | |
| US61/817,706 | 2013-04-30 | ||
| PCT/US2013/048771 WO2014005122A2 (en) | 2012-06-29 | 2013-06-28 | Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017207722A Division JP6709205B2 (ja) | 2012-06-29 | 2017-10-27 | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522033A JP2015522033A (ja) | 2015-08-03 |
| JP2015522033A5 true JP2015522033A5 (enExample) | 2016-08-18 |
| JP6236077B2 JP6236077B2 (ja) | 2017-11-22 |
Family
ID=49784044
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520604A Active JP6236077B2 (ja) | 2012-06-29 | 2013-06-28 | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 |
| JP2017207722A Active JP6709205B2 (ja) | 2012-06-29 | 2017-10-27 | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 |
| JP2020013449A Active JP7028474B2 (ja) | 2012-06-29 | 2020-01-30 | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017207722A Active JP6709205B2 (ja) | 2012-06-29 | 2017-10-27 | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 |
| JP2020013449A Active JP7028474B2 (ja) | 2012-06-29 | 2020-01-30 | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9156826B2 (enExample) |
| EP (1) | EP2867219B1 (enExample) |
| JP (3) | JP6236077B2 (enExample) |
| ES (1) | ES2625329T3 (enExample) |
| WO (1) | WO2014005122A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008145122A1 (en) † | 2007-05-31 | 2008-12-04 | Vestas Wind Systems A/S | A system for damping oscillations in a structure |
| EP2867219B1 (en) | 2012-06-29 | 2017-02-15 | Cornell University | Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration |
| WO2016056581A1 (ja) | 2014-10-08 | 2016-04-14 | 国立研究開発法人理化学研究所 | 植物成長促進剤及び植物成長促進方法 |
| CN110776481B (zh) * | 2018-07-24 | 2023-06-16 | 四川大学华西医院 | 一类双阳离子化合物及其制备方法和用途 |
| WO2021115413A1 (zh) * | 2019-12-11 | 2021-06-17 | 江苏恒瑞医药股份有限公司 | 神经肌肉阻滞剂及其制备方法 |
| US20230381192A1 (en) * | 2020-10-17 | 2023-11-30 | Cornell University | Methods for controlling and predicting recovery after nmba administration |
| CN113092656B (zh) * | 2021-02-22 | 2022-05-20 | 扬子江药业集团有限公司 | 一种注射用维库溴铵药物中有关物质的检测方法 |
| TW202434234A (zh) * | 2023-01-12 | 2024-09-01 | 大陸商西藏海思科製藥有限公司 | 雙季銨鹽化合物及其在醫藥上的應用 |
| WO2025140288A1 (zh) * | 2023-12-25 | 2025-07-03 | 上海森辉医药有限公司 | 一种四氢异喹啉及其药物用途 |
| WO2025140279A1 (zh) * | 2023-12-25 | 2025-07-03 | 上海森辉医药有限公司 | 季铵化合物及其药物用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8418303D0 (en) | 1984-07-18 | 1984-08-22 | Wellcome Found | Compounds |
| JP4112015B2 (ja) * | 1997-03-25 | 2008-07-02 | アベラ、ファーマスーティカルズ、インコーポレイテッド | 超短時間作用性神経筋遮断薬としての置換イソキノリン類 |
| GB0204087D0 (en) * | 2002-02-21 | 2002-04-10 | Legislator 1563 Ltd | Di-ester derivatives as short acting neuromuscular blockers |
| US20050192243A1 (en) * | 2003-10-28 | 2005-09-01 | Savarese John J. | Neuromuscular blocking agents and antagonists thereof |
| CN101588803B (zh) | 2006-12-06 | 2013-03-20 | 康乃尔研究基金会有限公司 | 中等持续时间神经肌肉阻断剂及其拮抗剂 |
| US8357805B2 (en) | 2007-06-18 | 2013-01-22 | Chemagis Ltd. | (1R,1′R)-atracurium salts separation process |
| WO2010107488A1 (en) | 2009-03-17 | 2010-09-23 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
| EP2867219B1 (en) | 2012-06-29 | 2017-02-15 | Cornell University | Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration |
-
2013
- 2013-06-28 EP EP13810090.4A patent/EP2867219B1/en active Active
- 2013-06-28 US US14/411,060 patent/US9156826B2/en active Active
- 2013-06-28 WO PCT/US2013/048771 patent/WO2014005122A2/en not_active Ceased
- 2013-06-28 ES ES13810090.4T patent/ES2625329T3/es active Active
- 2013-06-28 JP JP2015520604A patent/JP6236077B2/ja active Active
-
2017
- 2017-10-27 JP JP2017207722A patent/JP6709205B2/ja active Active
-
2020
- 2020-01-30 JP JP2020013449A patent/JP7028474B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522033A5 (enExample) | ||
| CA2915005C (en) | Use of eribulin and lenvatinib as combination therapy for treatment of cancer | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| CA2671904A1 (en) | Intermediate duration neuromuscular blocking agents and antagonists thereof | |
| JP2013542247A5 (enExample) | ||
| JP2013528600A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2013522229A5 (enExample) | ||
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| JP2011173928A5 (enExample) | ||
| RU2014109074A (ru) | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| JP2019515908A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2014508804A5 (enExample) | ||
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP2014505107A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| WO2015126816A1 (en) | Combination therapy for hematological malignancies | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| CN103889409A (zh) | N-羟基-4-{2-[3-(n,n-二甲基氨基甲基)苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的给药方案 | |
| JP2013523740A5 (enExample) |